➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Merck
McKinsey
Mallinckrodt
Boehringer Ingelheim
Johnson and Johnson
Harvard Business School

Last Updated: October 22, 2020

DrugPatentWatch Database Preview

Details for Patent: 6,652,880

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Which drugs does patent 6,652,880 protect, and when does it expire?

Patent 6,652,880 protects TAYTULLA and is included in one NDA.

This patent has thirty-one patent family members in twenty-three countries.

Summary for Patent: 6,652,880
Title: Oral pharmaceutical compositions containing long-chain triglycerides and liphophilic surfactants
Abstract:This invention is directed to pharmaceutical compositions for oral administration, wherein the drug or active ingredient is known to have stability problems associated with the use of free fatty acids. The compositions of the invention enhance the solubility of such compounds and improve the storage stability thereof and can be advantageously used in soft-gel and hard-shell capsular formulations. The liquid pharmaceutical compositions, according to the present invention, have a drug dissolved in a liquid vehicle. The liquid vehicle comprising a glyceride of a long chain fatty acid and a lypophilic surfactant having an HLB of less than ten. The composition, according to the invention, is also substantially free of free fatty acids.
Inventor(s): Aylwin; Elizabeth Anne (Swindon, GB), Banbury; Susan (Cheltenham, GB), Ferdinando; Josephine Joan Christine (Tadley, GB), de Nijs; Henrik (Oss, NL)
Assignee: R.P. Scherer Technologies, Inc. (Paradise Valley, NV)
Application Number:09/914,576
Patent Claim Types:
see list of patent claims
Composition; Dosage form;

Drugs Protected by US Patent 6,652,880

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Apil TAYTULLA ethinyl estradiol; norethindrone acetate CAPSULE;ORAL 204426-001 Apr 19, 2013 RX Yes Yes   Start Trial   Start Trial Y   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Foreign Priority and PCT Information for Patent: 6,652,880

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
United Kingdom9907715Apr 01, 1999
PCT Information
PCT FiledMarch 29, 2000PCT Application Number:PCT/US00/08426
PCT Publication Date:October 12, 2000PCT Publication Number: WO00/59482

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

AstraZeneca
McKinsey
Dow
Johnson and Johnson
Medtronic
McKesson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.